[go: up one dir, main page]

AR056991A1 - Derivados de urea, metodos para su fabricacion, y usos de los mismos - Google Patents

Derivados de urea, metodos para su fabricacion, y usos de los mismos

Info

Publication number
AR056991A1
AR056991A1 ARP060101666A ARP060101666A AR056991A1 AR 056991 A1 AR056991 A1 AR 056991A1 AR P060101666 A ARP060101666 A AR P060101666A AR P060101666 A ARP060101666 A AR P060101666A AR 056991 A1 AR056991 A1 AR 056991A1
Authority
AR
Argentina
Prior art keywords
groups
group
linear
same
different
Prior art date
Application number
ARP060101666A
Other languages
English (en)
Original Assignee
Proskelia S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proskelia S A S filed Critical Proskelia S A S
Publication of AR056991A1 publication Critical patent/AR056991A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treating Waste Gases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un proceso para su preparacion, su aplicacion por medio de medicamentos, y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1), donde: Y es oxígeno o azufre; R1 y R'1, son iguales o diferentes, y cada una representa un grupo arilo, un grupo heteroarilo, o R1 y R'1, junto con el átomo de carbono al cual están unidos, forman una estructura anular fusionada de formula (2), en la cual A representa un enlace simple, un grupo metileno, un grupo dimetileno, oxígeno, nitrogeno o azufre, estando dicho azufre opcionalmente en la forma de sulfoxido o sulfona; donde cada R1 y R'1, o dicha estructura anular fusionada formada de esta manera, está opcionalmente sustituida con al menos un sustituyente seleccionado del grupo c; donde el grupo c consiste en: átomos de halogeno, grupos hidroxilo, carboxilo, alquilo lineal o ramificado, hidroxialquilo; haloalquilo, alquiltio, alquenilo y alquinilo; grupos alcoxilo lineales y ramificados; grupos tioalquilo lineal y ramificados; hidroxicarbonilalquilo; alquilcarbonilo; alcoxicarbonilalquilo; carbonilo; trifluorometilo; trifluorometoxilo; -CN, -NO2; grupos alquilsulfonilo opcionalmente en las formas sulfoxido o sulfona; donde cualquier componente alquilo C1-6 y cualquiera alquenilo o alquinilo C2-6; y donde, cuando hay más de un sustituyente, entonces cada sustituyentes es igual o diferente; R2 y R'2, el cual puede ser el mismo o diferente, cada uno representa: un átomo de hidrogeno; un grupo alquilo lineal o ramificado C1-6 y opcionalmente está sustituido al menos con un átomo de halogeno, grupo hidroxi o alcoxi C1-6; un grupo alquilaminoalquilo o dialquilaminoalquilo donde cada grupo alquilo contiene C1-6; o R2 y R'2, junto con el átomo de nitrogeno al cual están unidos forman un heterociclo saturado o insaturado que contiene 0, 1 o 2 heteroátomos adicionales y que tienen 5, 6 o 7 átomos anulares, estando dicho grupo heterociclo opcionalmente sustituido por al menos un sustituyente seleccionado del grupo ôcö definido anteriormente; y donde, cuando hay más de un sustituyente, dicho sustituyente es igual o diferente; R3 representa un grupo de formula (3) o (4), en la cual B representa un átomo de oxígeno o un átomo de azufre, x es 0, 1 o 2, y e y' son iguales o diferentes, y cada uno es 0 o 1, Ar y Ar' son iguales o diferentes y cada uno representa un grupo arilo o heteroarilo, n y n' son iguales o diferentes y cada uno es 1, cuando el y o y' con el cual este se asocia es 0, o es igual al numero de posiciones que se pueden sustituir en el Ar o Ar' asociado cuando dicho y o y' es 1, el anillo fusionado que contiene Nx es un anillo heteroarilo de cinco o seis miembros, y donde R y R', que pueden ser iguales o diferentes, cada uno representa un átomo de hidrogeno o un sustituyente seleccionado del grupo a; donde el grupo a consiste en: átomos de halogeno, grupos hidroxilo; carboxilo; aldehído; alquilo lineal y ramificado, alquenilo, alquinilo, hidroxialquilo, hidroxialquenilo, hidroxialquinilo, haloalquilo, haloalquenilo, y haloalquinilo; grupos alcoxilo lineal o ramificados; grupos tioalquilo lineal o ramificados; grupos aralcoxi; grupos ariloxi; alcoxicarbonilo; aralcoxicarbonilo; ariloxicarbonilo; hidroxicarbonilalquilo; alcoxicarbonilalquilo; aralcoxicarbonilalquilo; ariloxicarbonilalquilo; perfluoroalquilo; perfluoroalcoxi; -CN; acilo; amino; alquilamino; aralquilamino; arilamino; dialquilamino; diaralquilamino; grupos diarilamino; acilamino y diacilamino; grupos alcoxicarbonilamino, aralcoxicarbonilamino, ariloxicarbonilamino, alquilcarbonilamino, aralquilcarbonilamino y arilcarbonilamino; grupos alquilaminocarboniloxi, aralquilaminocarboniloxi y arilaminocarboniloxi; grupos alquilo sustituidos con un amino, grupos alquilamino, aralquilamino, arilamino, dialquilamino, diaralquilamino, diarilamino, acilamino, trifluorometilcarbonil-amino, fluoroalquilcarbonilamino o diacilamino; CONH2; grupos alquil-aralquil- y arilamido; alquiltio, ariltio y aralquiltio y sus formas oxidadas sulfoxido y sulfona; grupos sulfonilo, alquilsulfonilo, haloalquilsulfonilo, arilsulfonilo y aralquilsulfonilo; sulfonamida, alquilsulfonamida, haloalquilsulfonamida, di(alquilsulfonil)amino, y grupos heterociclilo saturados e insaturados, siendo dichos grupos heterociclilo mono- o bi-cíclico y estando sustituidos opcionalmente con uno o más sustituyentes, que pueden ser iguales o diferentes, seleccionados del grupo b; donde el grupo b consiste en: átomos de halogeno, grupos hidroxilo; carboxilo; aldehído; alquilo lineal y ramificado, alquenilo, alquinilo, hidroxialquilo, grupos hidroxialquenilo, hidroxialquinilo, haloalquilo, haloalquenilo, y haloalquinilo; grupos alcoxilo lineal o ramificados; grupos tioalquilo lineal o ramificado; hidroxicarbonilalquilo; grupos alcoxicarbonilalquilo; perfluoroalquilo; perfluoroalcoxi; -CN; acilo; amino; alquilamino; dialquilamino; acilamino y diacilamino; grupos alquilo sustituidos con un grupo amino, alquilamino, dialquilamino, acilamino o diacilamino; CONH2; grupos alquilamido; alquiltio, y sus formas oxidadas sulfoxido y sulfona; grupos sulfonilo, alquilsulfonilo, y sulfonamida, alquilsulfonamida, y di(alquilsulfonil)amino; donde, en los grupos a y b, cualquiera de los componentes alquilo contiene C1-6, y cualquier componente alquenilo o alquinilo contiene C2-6, y está opcionalmente sustituido con al menos un átomo de halogeno o grupo hidroxi, y donde cualquier componente arilo está opcionalmente sustituido con un grupo heteroarilo; y sus sales y ésteres.
ARP060101666A 2005-04-29 2006-04-26 Derivados de urea, metodos para su fabricacion, y usos de los mismos AR056991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0504360A FR2885129B1 (fr) 2005-04-29 2005-04-29 Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.

Publications (1)

Publication Number Publication Date
AR056991A1 true AR056991A1 (es) 2007-11-07

Family

ID=35311522

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101666A AR056991A1 (es) 2005-04-29 2006-04-26 Derivados de urea, metodos para su fabricacion, y usos de los mismos

Country Status (25)

Country Link
US (2) US8247412B2 (es)
EP (2) EP1874765B1 (es)
JP (1) JP4995189B2 (es)
KR (1) KR20080003380A (es)
CN (1) CN101238120A (es)
AR (1) AR056991A1 (es)
AT (1) ATE548368T1 (es)
AU (1) AU2006243328B2 (es)
BR (1) BRPI0611025A2 (es)
CA (1) CA2605008A1 (es)
CR (1) CR9469A (es)
CY (1) CY1112960T1 (es)
DK (1) DK1874765T3 (es)
EA (1) EA200702375A1 (es)
ES (1) ES2384052T3 (es)
FR (1) FR2885129B1 (es)
HR (1) HRP20120424T1 (es)
IL (1) IL186854A0 (es)
NO (1) NO20076145L (es)
PL (1) PL1874765T3 (es)
PT (1) PT1874765E (es)
TW (1) TW200714598A (es)
UY (1) UY29510A1 (es)
WO (1) WO2006117211A2 (es)
ZA (1) ZA200708871B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
WO2007060026A1 (en) * 2005-11-25 2007-05-31 Galapagos Sas Urea derivatives useful as calcium receptor modulators
EA200802166A1 (ru) * 2006-04-20 2009-06-30 Эмджен Инк. Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
ES2499015T3 (es) * 2007-05-08 2014-09-26 Ajinomoto Co., Inc. Agente profiláctico o terapéutico para la diarrea
EP2176247A2 (en) * 2007-07-10 2010-04-21 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
RS62915B1 (sr) * 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物
WO2019222393A1 (en) * 2018-05-15 2019-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotective compositions and methods of using the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31574A0 (en) 1968-02-13 1969-04-30 Ciba Ltd Use of certain ureas for combating weeds
US3897242A (en) 1968-02-13 1975-07-29 Ciba Geigy Ag Use of 1-(3-chloro-4-methylphenyl)-3,3-dimethylurea in wheat and barley crops
JPS58109464A (ja) 1981-12-23 1983-06-29 Nippon Paint Co Ltd アミノ酸化合物、その製法ならびに触媒
US4579947A (en) 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
US4594373A (en) 1984-02-09 1986-06-10 American Cyanamid Company Curable epoxy resin compositions
US4521583A (en) 1984-02-09 1985-06-04 American Cyanamid Company Curable epoxy resin compositions
FR2601363B1 (fr) * 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DD298412A5 (de) 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
US5227397A (en) 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
AU5957390A (en) 1989-07-03 1991-02-06 New York University Use of polyamines as ionic-channel regulating agents
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
EP0558657B1 (en) 1990-11-19 1997-01-08 Monsanto Company Retroviral protease inhibitors
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
PT724561E (pt) 1991-08-23 2004-07-30 Nps Pharma Inc Arilalquil-aminas como receptores activos de calcio
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ES2091000T3 (es) 1992-05-20 1996-10-16 Searle & Co Metodo para elaborar intermedios utiles en la sintesis de inhibidores de proteasas retroviricas.
EP1090914B1 (en) 1992-12-29 2003-01-02 Abbott Laboratories Retroviral protease inhibiting compounds
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
WO1996012697A2 (en) 1994-10-21 1996-05-02 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
ES2145929T3 (es) 1994-11-04 2000-07-16 Santen Pharmaceutical Co Ltd Nuevo derivado de 1,3-dialquil-urea que tiene un grupo hidroxilo.
WO1996018606A1 (en) 1994-12-14 1996-06-20 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivatives
JP3306571B2 (ja) 1995-06-28 2002-07-24 参天製薬株式会社 エンドセリン変換酵素阻害剤
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
JPH10195037A (ja) 1996-02-15 1998-07-28 Tanabe Seiyaku Co Ltd フェノール誘導体
EA002984B1 (ru) 1996-04-09 2002-12-26 Эн Пи Эс Фармасьютикалз, Инк. Кальцилитические соединения, фармацевтические композиции и способ скрининга кальцилитических соединений
AU8534198A (en) 1997-08-05 1999-03-01 Novo Nordisk A/S Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
CA2284864A1 (en) 1998-01-21 1999-07-29 Zymogenetics, Inc. Dialkyl ureas as calcitonin mimetics
CN1348370A (zh) 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
US6365617B1 (en) * 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
FR2820136A1 (fr) * 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6598746B2 (en) * 2001-09-13 2003-07-29 Washburn Graphics, Inc. Display carton having an internally reinforced hanger panel
TW200412956A (en) 2002-09-30 2004-08-01 Schering Corp Methods for treating disorders of calcium homeostasis
JP2005336173A (ja) * 2004-04-27 2005-12-08 Santen Pharmaceut Co Ltd 骨粗鬆症治療剤
PL1757582T3 (pl) 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
CA2608957C (en) 2005-05-19 2013-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
WO2007060026A1 (en) 2005-11-25 2007-05-31 Galapagos Sas Urea derivatives useful as calcium receptor modulators
GB0613674D0 (en) 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
EP2176247A2 (en) 2007-07-10 2010-04-21 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor

Also Published As

Publication number Publication date
AU2006243328B2 (en) 2011-09-08
CY1112960T1 (el) 2016-04-13
TW200714598A (en) 2007-04-16
WO2006117211A3 (en) 2007-01-11
FR2885129B1 (fr) 2007-06-15
CR9469A (es) 2008-03-06
US20100240889A1 (en) 2010-09-23
US8247412B2 (en) 2012-08-21
BRPI0611025A2 (pt) 2016-11-16
EP2354137A1 (en) 2011-08-10
HRP20120424T1 (hr) 2012-06-30
EP1874765B1 (en) 2012-03-07
DK1874765T3 (da) 2012-06-18
UY29510A1 (es) 2006-12-29
PL1874765T3 (pl) 2012-08-31
NO20076145L (no) 2008-01-28
ES2384052T3 (es) 2012-06-28
WO2006117211A2 (en) 2006-11-09
PT1874765E (pt) 2012-05-25
EP1874765A2 (en) 2008-01-09
AU2006243328A1 (en) 2006-11-09
US20120283255A1 (en) 2012-11-08
ZA200708871B (en) 2009-03-25
EA200702375A1 (ru) 2008-06-30
ATE548368T1 (de) 2012-03-15
KR20080003380A (ko) 2008-01-07
IL186854A0 (en) 2008-02-09
JP2008539186A (ja) 2008-11-13
JP4995189B2 (ja) 2012-08-08
CN101238120A (zh) 2008-08-06
CA2605008A1 (en) 2006-11-09
FR2885129A1 (fr) 2006-11-03

Similar Documents

Publication Publication Date Title
AR056991A1 (es) Derivados de urea, metodos para su fabricacion, y usos de los mismos
PE20230162A1 (es) Derivados espirancos sustituidos de cadena lineal
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR055606A1 (es) Derivados de benzoquinazolina
AR061374A1 (es) Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos
AR056686A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
AR055620A1 (es) Derivados de cicloalcano-carboxamidas
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR070925A1 (es) 4- hidroxipirimidina -5- carboxamida sustituidas, un procedimiento para el tratamiento preventivo de anemia, procedimiento para potenciar la produccion endogena de eritropoyetina, uso del compuesto en la fabricacion de un medicamento y composicion farmaceutica
AR072791A1 (es) DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER.
AR038172A1 (es) Compuesto de ciclohexano y ciclohexeno, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica, procedimiento para preparar el compuesto y compuestos intermediarios en dicho procedimiento
AR091790A1 (es) Derivados de isoquinolin-1-ona y sus usos
AR061583A1 (es) Acidos 6-(bencilo sustituido con heterociclil)-4-oxiquinolin carboxilicos, inhibidores de vih-integrasas, composiciones farmaceuticas que los contienen y usos como agentes anti-vih.
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR035858A1 (es) Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
AR068061A1 (es) Derivados de bisamida biciclicos utiles como pesticidas
AR061643A1 (es) Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1.
AR045388A1 (es) Inhibidores del c-kit imidazopiridinicos n3-sustituidos
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.

Legal Events

Date Code Title Description
FB Suspension of granting procedure